Cullinan Therapeutics

Cullinan Therapeutics

Cullinan Therapeutics was founded in 2017 and previously operated as Cullinan Oncology, taking its name from the gemstone conglomerate to reflect its portfolio-of-assets architecture. The original model, conceived by founding CEO Owen Hughes and backers including F2 Ventures and MPM Capital, created independent subsidiaries — each a distinct legal entity with its own management and scientific focus — to advance oncology drug candidates in parallel. The firm raised over $600 million across private rounds and its 2021 initial public offering before consolidating its corporate structure under a unified pipeline and rebranding to Cullinan Therapeutics in 2024. The company develops targeted oncology and immunology therapies, with a lead asset in clinical trials for autoimmune diseases — a strategic pivot from pure oncology that the new brand was designed to encompass. Its pipeline spans bispecific T-cell engagers, monoclonal antibodies, and small-molecule programs. CLN-978, a CD19-directed T-cell engager, is in Phase 1 studies for systemic lupus erythematosus (per the firm's pipeline disclosures, 2025). A prior lead candidate, CLN-081, was licensed to Taiho Oncology in a deal that validated the model's ability to carve out and monetize single assets. The firm operates across the United States and collaborates with academic cancer centers and global contract research organizations for clinical execution. Corporate records show Cullinan employed roughly 85 professionals at the time of its 2024 strategic restructuring. The firm maintains its headquarters in Cambridge, Massachusetts — a dense biotech cluster — and has conducted clinical operations across sites in the United States, Europe, and Asia-Pacific. Jeffrey Trigilio, who joined as CFO in 2021, had previously steered finances at Akcea Therapeutics through its acquisition by Ionis Pharmaceuticals. January 2024: Nadim Ahmed was appointed President and CEO, replacing Owen Hughes; the firm simultaneously rebranded from Cullinan Oncology to Cullinan Therapeutics and announced a registered direct offering priced at-the-market for $25 million (per the firm, January 2024). The defining architectural feature is a disciplined capital-allocation system that originated with a decentralized subsidiary model and persists as a pipeline-rationalization mandate. Under Ahmed — who previously led the global CAR-T franchise at Bristol Myers Squibb and served as CEO of private biotech Umoja Biopharma — Cullinan has sharpened its focus to a concentrated set of immunology programs. This transition from incubation platform to therapeutic-focused company represents a different species of biotech that treats asset selection as a capital-markets function, not a R&D habit.